Pfizer
Foreign minister S Jaishankar arrives in US, to discuss Covid-related cooperation with officials
Dhaka, May 24 (UNB)--External Affairs Minister (EAM) S Jaishankar on Monday landed in New York, as part of his US visit, to meet with senior United States officials, and discuss Covid-related cooperation between the two countries, reports Hindustan Times.
Ambassador of India to the UN TS Tirumurti received EAM Jaishankar on his first visit to New York after India entered the UN Security Council.
"Privilege to receive External Affairs Minister @DrSJaishankar on his first visit to New York after #India entered the UN #SecurityCouncil on 1 January 2021," Ambassador Tirumurti tweeted.
Jaishankar's US visit is slated to last till May 28, the External Affairs Ministry said last week.
Read: India may firm up plans to export Bharat Biotech’s Covaxin
The Foreign Minister is expected to meet UN Secretary-General Antonio Guterres in New York and later he will hold discussions with his counterpart Secretary of State Antony Blinken in Washington DC, the ministry said.
He will also be meeting Cabinet members and Senior Officials of the Administration dealing with the bilateral relationship. "External Affairs Minister will have two interactions with business forums on economic and Covid-related cooperation between India and the US," said the ministry statement.
According to Hindustan Times, India is engaged in talks with various US entities involved in Covid vaccines production and is looking forward to procuring and subsequently producing these vaccines. The issue of vaccine procurement is expected to be a key agenda item during Jaishankar's interaction with US leadership and other stakeholders.
The US has already announced that it is going to distribute 80 million vaccines from its stockpile to countries in need.
With India hit badly by the second Covid wave, efforts of New Delhi will focus on getting the maximum and also looking for tie-ups with vaccine developers to produce in India.
US has a stockpile 60 million Astra Zeneca vaccine doses and also Pfizer, Moderna and Johnson & Johnson Covid-19 vaccines.
Read: India virus death toll passes 300,000, 3rd highest in world
US is playing a lead role in assisting India's fight against the Covid-19 virus. It has already provided large oxygen plants, concentrators, critical medicines like Remdesivir and also raw materials for vaccine manufacturer Serum Institute of India (SII), which is manufacturing Covishield.
US is also backing India sponsored proposal on TRIPS waiver at the WTO.
The TRIPS waiver aims to increase global vaccine production in order to take on the challenge of vaccinating the poorest of the poor and save lives.
In October last year, India and South Africa, along with 57 members of WTO proposed a waiver from certain provisions of the TRIPS agreement for prevention, containment, and treatment of the coronavirus. EAM Jaishankar met his US counterpart Antony Blinken in early May in London during G7 Foreign Minister's meeting.
Bangladesh to get 106,000 doses of Pfizer vaccine on June 2: Health Ministry
Bangladesh will receive a minimum of 1,06,000 doses of Pfizer vaccine by June 2, Health Minister Zahid Maleque said Tuesday.
The doses will be sent to Bangladesh under the COVAX scheme which is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI), UNICEF and the World Health Organization (WHO), said Maidul Islam, the public relation officer of the ministry.
Also read: Bangladesh seeks at least 2 mln doses of AstraZeneca vaccine from Canada
The Pfizer BioNTech vaccine has an efficacy of 95% against symptomatic SARS-CoV-2 infection.
However, preliminary laboratory studies of the mRNA vaccines by Pfizer and Moderna have shown decreased effectiveness against the double mutant variants discovered in India, WHO said in a note.
Read: Vaccine production in Bangladesh: Experts 'vehemently against private sector’s engagement'
Britain yet to decide on Pfizer offer to vaccinate Olympians
The British government is still deciding whether to accept an offer from Pfizer to fast-track Olympic and Paralympic athletes for coronavirus vaccines.
Jabs are only being given to Britons aged 38 or older - though this will be extended to those over 35 from next week - with younger people only getting inoculated if they have an underlying health condition.
It s sensitive because the philosophy has been based on age and that s been proved to be the right thing, British Sports Minister Nigel Huddleston said. The biggest indicator is age is the biggest factor and of course Pfizer have offered for the Olympics and we ve asked them about that.
Pfizer, which developed a vaccine with BioNTech, said earlier this month said that it would donate doses to inoculate athletes and officials preparing for the Tokyo games with the rescheduled Olympics due to open on July 23.
While the Olympics begin in less than 10 weeks, Britain has a policy of delaying the second dose by up to 12 weeks to free up vaccines for more people. Britain announced Sunday that more than 20 million people have now received both doses. The two shots of the Pfizer vaccines were intended to be given three to four weeks apart.
The government s vaccine rollout has been excellent and, coupled with the IOC s donation of the Pfizer vaccine for athletes, means we are hopeful of getting all athletes vaccinated before they travel to Tokyo, British Olympic Association chairman Hugh Robertson said. It is important for this to happen soon, to assure our hosts in Tokyo that we are doing all we can to keep their population safe.
Belgium, France, Germany, Italy and Spain are among the European nations to have already offered vaccines to delegations headed to Tokyo.
Japan has been struggling to slow infections ahead of the games and expanded a coronavirus state of emergency from six areas, including Tokyo, to nine on Friday.
More support easing vaccine patent rules, but hurdles remain
Several world leaders Thursday praised the U.S. call to remove patent protections on COVID-19 vaccines to help poor countries obtain shots. But the proposal faces a multitude of hurdles, including resistance from the pharmaceutical industry.
Nor is it clear what effect such a step might have on the campaign to vanquish the outbreak.
Activists and humanitarian institutions cheered after the U.S. reversed course Wednesday and called for a waiver of intellectual property protections on the vaccine. The decision ultimately is up to the 164-member World Trade Organization, and if just one country votes against a waiver, the proposal will fail.
The Biden administration announcement made the U.S. the first country in the developed world with big vaccine manufacturing to publicly support the waiver idea floated by India and South Africa in October. On Thursday, French President Emmanuel Macron embraced it as well.
“I completely favor this opening up of the intellectual property,” Macron said at a vaccine center.
However, like many pharmaceutical companies, Macron insisted that a waiver would not solve the problem of access to vaccines. He said manufacturers in places like Africa are not now equipped to make COVID-19 vaccines, so donations of shots from wealthier countries should be given priority instead.
Pfizer, Moderna, Johnson & Johnson and AstraZeneca — all companies with licensed COVID-19 vaccines — had no immediate comment, though Moderna has long said it will not pursue rivals for patent infringement during the pandemic.
Also read: US tribe shares vaccine with relatives, neighbors in Canada
U.S. Secretary of State Antony Blinken underscored the urgency of moving fast now.
“On the current trajectory, if we don’t do more, if the entire world doesn’t do more, the world won’t be vaccinated until 2024,” he said in an interview with NBC while visiting Ukraine.
India, as expected, welcomed the move. Australian Prime Minister Scott Morrison called the U.S. position “great news.”
Italian Foreign Minister Luigi Di Maio wrote on Facebook that the U.S. announcement was “a very important signal” and that the world needs “free access” to vaccine patents. But Italian Premier Mario Draghi was more circumspect.
Russian President Vladimir Putin said his country would support it. U.N. Secretary-General Antonio Guterres welcomed the U.S. decision too.
But German Chancellor Angela Merkel’s office spoke out against it, saying: “The protection of intellectual property is a source of innovation and must remain so in the future.”
Also read: US support behind vaccine patent waiver ‘monumental moment’ in Covid fight: WHO
A Merkel spokeswoman, speaking on customary condition of anonymity, said Germany is focused instead on how to increase vaccine manufacturers’ production capacity.
In Brazil, one of the deadliest COVID-19 hot spots in the world, Health Minister Marcelo Queiroga said he fears that the country does not have the means to produce vaccines and that the lifting of patent protections could interfere with Brazil’s efforts to buy doses from pharmaceutical companies.
In closed-door talks at the WTO in recent months, Australia, Britain, Canada, the European Union, Japan, Norway, Singapore and the United States opposed the waiver idea, according to a Geneva-based trade official who was not authorized the discuss the matter and spoke on condition of anonymity.
Some 80 countries, mostly developing ones, have supported the proposal, the official said. China and Russia — two other major COVID-19 vaccine makers — didn’t express a position but were open to further discussion, the official said.
EU Commission President Ursula von der Leyen said the 27-nation bloc is ready to talk about the idea, but she remained noncommittal and emphasized that the EU has been exporting vaccines widely — while the U.S. has not.
EU leaders said the bloc may discuss the matter at a summit that starts Friday.
Also read: US backs waiving intellectual property rules on vaccines
The pharmaceutical industry has argued that a waiver will do more harm than good in the long run.
Easing patent protections would eat into their profits, potentially reducing the incentives that push companies to innovate and make the kind of tremendous leaps they did with the COVID-19 vaccines, which have been churned out at a blistering, unprecedented pace.
The industry has contended, too, that production of the vaccines is complicated and can’t be ramped up simply by easing patent rights. Instead, it has said that reducing snarls in supply chains and shortages of ingredients is a more pressing issue.
The industry has insisted that a faster solution would be for rich countries to share their vaccine stockpiles with poorer ones.
“A waiver is the simple but the wrong answer to what is a complex problem,” said the International Federation of Pharmaceutical Manufacturers and Associations. “Waiving patents of COVID-19 vaccines will not increase production nor provide practical solutions needed to battle this global health crisis.”
Intellectual property law expert Shyam Balganesh, a professor at Columbia University, said a waiver would only go so far because of bottlenecks in the manufacturing and distribution of vaccines.
Also read: EU medicine regulator starts rolling review of Sinovac COVID-19 vaccine
Backers of the waiver say that expanded production by the big pharmaceutical companies and donations from richer countries to poor ones won’t be enough, and that there are manufacturers standing by that could make the vaccines if given the blueprints.
“A waiver of patents for #COVID19 vaccines & medicines could change the game for Africa, unlocking millions more vaccine doses & saving countless lives,” World Health Organization Africa chief Matshidiso Moeti tweeted.
Just over 20 million vaccine doses have been administered across the African continent, which has 1.3 billion people.
There is precedent: In 2003, WTO members agreed to waive patent rights and allow poorer countries to import generic treatments for the AIDS virus, malaria and tuberculosis.
“We believe that when the history of this pandemic is written, history will remember the move by the U.S. government as doing the right thing at the right time,” Africa CDC Director John Nkengasong said.
COVAX reaches over 100 economies, 42 days after first international delivery
More than one hundred economies have received life-saving COVID-19 vaccines from COVAX, the global mechanism for equitable access to COVID-19 vaccines, says the World Health Organization (WHO) on Thursday.
The milestone comes 42 days after the first COVAX doses were shipped and delivered internationally, to Ghana on 24 February 2021.
COVAX has now delivered more than 38 million doses across six continents, supplied by three manufacturers, AstraZeneca, Pfizer-BioNTech and the Serum Institute of India (SII).
Of the over 100 economies reached, 61 are among the 92 lower-income economies receiving vaccines funded through the Gavi COVAX Advance Market Commitment (AMC).
Despite reduced supply availability in March and April – the result of vaccine manufacturers scaling and optimizing their production processes in the early phase of the rollout, as well as increased demand for COVID-19 vaccines in India – COVAX expects to deliver doses to all participating economies that have requested vaccines in the first half of the year.
Also read: Covishield and Covaxin: What we know about India's Covid-19 vaccines
“In four months since the very first mass vaccination outside a clinical setting anywhere in the world, it is tremendously gratifying that the roll-out of COVAX doses has already reached one hundred countries,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance.
Berkley said COVAX may be on track to deliver to all participating economies in the first half of the year yet they still face a daunting challenge as they seek to end the acute stage of the pandemic: they will only be safe when everybody is safe and our efforts to rapidly accelerate the volume of doses depend on the continued support of governments and vaccine manufacturers.
“As we continue with the largest and most rapid global vaccine rollout in history, this is no time for complacency.”
Dr Tedros Adhanom Ghebreyesus, WHO Director-General said COVAX has given the world the best way to ensure the fastest, most equitable rollout of safe and effective vaccines to all at-risk people in every country on the planet.
Also read: ‘We sink or we swim together’: 5 things you need to know about COVAX
“If we are going to realize this great opportunity, countries, producers and the international system must come together to prioritize vaccine supply through COVAX. Our collective future, literally, depends on it.”
Dr Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations (CEPI) this is a significant milestone in the fight against COVID-19. “Faced with the rapid spread of COVID-19 variants, global access to vaccines is fundamentally important to reduce the prevalence of the disease, slow down viral mutation, and hasten the end of the pandemic.”
“In just a month and a half, the ambition of granting countries access to COVID vaccines is becoming a reality, thanks to the outstanding work of our partners in the COVAX Facility,” said Henrietta Fore, UNICEF Executive Director.
“However, this is no time to celebrate; it is time to accelerate. With variants emerging all over the world, we need to speed up global rollout. To do this, we need governments, along with other partners, to take necessary steps to increase supply, including by simplifying barriers to intellectual property rights, eliminating direct and indirect measures that restrict exports of COVID-19 vaccines, and donating excess vaccine doses as quickly as possible.”
Also read: WHO calls for prioritising vaccine contracts with COVAX
According to its latest supply forecast, COVAX expects to deliver at least 2 billion doses of vaccines in 2021. In order to reach this goal, the COVAX Facility will continue to diversify its portfolio further, and will announce new agreements with vaccine manufacturers in due course.
Furthermore, in March it was announced that the United States government will host the launch event for the 2021 Gavi COVAX AMC Invest Opportunity to catalyze further commitment and support for accelerated access to vaccines for AMC-supported economies.
An additional US$ 2 billion is required in 2021 to finance and secure up to a total of 1.8 billion donor-funded doses of vaccines. COVAX is also working to secure additional sourcing of vaccines in the form of dose-sharing from higher income countries.
The Latest: Pfizer: Vaccine effective up to 6 months later
Pfizer says its vaccine continues to be effective against COVID-19 up to six months later.
Pfizer and its German partner, BioNTech, announced updated results Thursday from their ongoing late-stage study of more than 44,000 volunteers.
Also read: Pfizer says its COVID-19 vaccine protects younger teens
The companies said the vaccine was 91% effective against symptomatic disease and was even more protective in preventing severe disease. Of 927 confirmed COVID-19 cases detected through March 13, 77 were among people who received the vaccine and 850 were among people who got dummy shots.
There were no serious safety concerns and the vaccine also appeared to work against a variant first detected in South Africa, the companies said.
Also read: Pfizer studying effects of 3rd vaccine dose
The U.K. and U.S. gave the emergency green light to roll out Pfizer’s vaccine late last year followed by many other countries. The vaccine is authorized for ages 16 and up.
This week, the companies said the vaccine is safe and strongly protective in kids as young as 12, based on a study of 2,260 U.S. volunteers.
Also read: Pfizer COVID-19 vaccine works well in big ‘real world’ test
Pfizer says its COVID-19 vaccine protects younger teens
Pfizer announced Wednesday that its COVID-19 vaccine is safe and strongly protective in kids as young as 12, a step toward possibly beginning shots in this age group before they head back to school in the fall.
Most COVID-19 vaccines being rolled out worldwide are for adults, who are at higher risk from the coronavirus. Pfizer’s vaccine is authorized for ages 16 and older. But vaccinating children of all ages will be critical to stopping the pandemic — and helping schools, at least the upper grades, start to look a little more normal after months of disruption.
In the vaccine study of 2,260 U.S. volunteers ages 12 to 15, preliminary data showed there were no cases of COVID-19 among fully vaccinated adolescents compared to 18 among those given dummy shots, Pfizer reported.
It’s a small study, that hasn’t yet been published, so another important piece of evidence is how well the shots revved up the kids’ immune systems. Researchers reported high levels of virus-fighting antibodies, somewhat higher than were seen in studies of young adults.
Kids had side effects similar to young adults, the company said. The main side effects are pain, fever, chills and fatigue, particularly after the second dose. The study will continue to track participants for two years for more information about long-term protection and safety.
Dr. Philip J. Landrigan of Boston College said the results are encouraging.
“It’s hard to get kids to comply with masking and distancing, so something that gives them hard protection and takes them out of the mix of spreading the virus is all for the good,” said Landrigan, who was not involved in the study.
Also read: Hong Kong halts use of Pfizer vaccine, cites defective lids
It’s another positive development in the race against the virus even as U.S. cases, at 66,000 new infections a day, are rising again and deaths are averaging nearly 1,000 a day. Centers for Disease Control and Prevention director Dr. Rochelle Walensky warned Americans again Wednesday that “we can’t afford to let our guard down.”
Pfizer and its German partner BioNTech in the coming weeks plan to ask the U.S. Food and Drug Administration and European regulators to allow emergency use of the shots starting at age 12.
“We share the urgency to expand the use of our vaccine,” Pfizer CEO Albert Bourla said in a statement. He expressed “the hope of starting to vaccinate this age group before the start of the next school year” in the United States.
Pfizer isn’t the only company seeking to lower the age limit for its vaccine. Results also are expected by the middle of this year from a U.S. study of Moderna’s vaccine in 12- to 17-year-olds.
But in a sign that the findings were promising, the FDA already allowed both companies to begin U.S. studies in children 11 and younger, working their way to as young as 6-month-old.
Also read: US approves Pfizer vaccine storage for 2 weeks at higher temperature
“We are longing for a normal life. This is especially true for our children,” BioNTech CEO Ugur Sahin said in a statement.
AstraZeneca last month began a study of its vaccine among 6- to 17-year-olds in Britain. Johnson & Johnson is planning its own pediatric studies. And in China, Sinovac recently announced it has submitted preliminary data to Chinese regulators showing its vaccine is safe in children as young as 3.
While most COVID-19 vaccines being used globally were first tested in tens of thousands of adults, pediatric studies won’t need to be nearly as large. Scientists have safety information from those studies and from subsequent vaccinations in millions more adults.
One key question is the dosage: Pfizer gave the 12-and-older participants the same dose adults receive, while testing different doses in younger children.
It’s not clear how quickly the FDA would act on Pfizer’s request to allow vaccination starting at age 12. The agency has taken about three weeks to review and authorize each of the vaccines currently available for adults. That process included holding a public meeting of outside experts to review and vote on the safety and effectiveness of each shot.
Also read: Pfizer COVID-19 vaccine works well in big 'real world' test
The process for reviewing data in children could be shorter, given FDA’s familiarity with each vaccine. An agency spokeswoman said the FDA had no information to share on how the review would work, including whether additional public meetings would be required.
Another question is when the country would have enough supply of shots — and people to get them into adolescents’ arms — to let kids start getting in line.
Supplies are set to steadily increase over the spring and summer, at the same time states are opening vaccinations to younger, healthier adults who until now haven’t had a turn.
Children represent about 13% of COVID-19 cases documented in the U.S. And while children are far less likely than adults to get seriously ill, at least 268 have died from COVID-19 in the U.S. alone and more than 13,500 have been hospitalized, according to a tally by the American Academy of Pediatrics. That’s more than die from the flu in an average year. Additionally, a small number have developed a serious inflammatory condition linked to the coronavirus.
Caleb Chung, who turns 13 later this week, agreed to volunteer after his father, a Duke University pediatrician, presented the option. He doesn’t know if he received the vaccine or a placebo.
“Usually I’m just at home doing online school and there’s not much I can really do to fight back against the virus,” Caleb said in a recent interview. The study “was really somewhere that I could actually help out.”
His father, Dr. Richard Chung, said he’s proud of his son and all the other children volunteering for the needle pricks, blood tests and other tasks a study entails.
“We need kids to do these trials so that kids can get protected. Adults can’t do that for them,” Chung said.
SAGE approves 'safe and lifesaving' Janssen Covid jab
The UN health agency expert advisory board, SAGE, has approved the Janssen Covid-19 vaccine for international use, allaying concerns over clotting events being associated by some countries, without definitive evidence, with coronavirus jabs.
When will children be able to get COVID-19 vaccines?
When will children be able to get COVID-19 vaccines?
South Korea allows workers to squeeze extra doses
South Korea’s Disease Control and Prevention Agency has allowed health workers to squeeze extra doses from vials of coronavirus vaccines developed by AstraZeneca and Pfizer.